Iovance Biotherapeutics, Inc. IOVA Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s change in lease liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported change in lease liabilities of -$2.03M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s change in lease liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s change in lease liabilities increased by 34.9% year-over-year, from -$3.11M to -$2.03M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s change in lease liabilities?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s change in lease liabilities has grown at a 16.7% compound annual growth rate (CAGR), from -$5.88M to -$10.9M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.